Navigation Links
New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings
Date:12/7/2009

anies, Monheim, Germany; 2 Department of Neurology, Johns Hopkins Epilepsy Center, Baltimore, Maryland, United States, 21287; 3 SCHWARZ BIOSCIENCES, Inc., RTP, NC, United States; 4 UCB, Inc., Atlanta, GA, United States

Abstract: A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report

In this study, patients currently taking one to two AEDs were grouped into three, 25-patient cohorts and given three progressively increasing doses of intravenous lacosamide (200 mg, 300 mg and 400 mg) administered via 15-minute infusions, followed by the same dose of the oral form given twice-daily for 6.5 days.

The first three cohorts (200 mg, 300 mg and 400 mg loading dose) have completed the trial. All subjects in the first cohort (200 mg loading dose) completed the trial. One subject (4 percent) from the second cohort (300 mg loading dose) and four subjects (16 percent) from the third cohort (400 mg loading dose) withdrew due to adverse events.

Based on results of these cohorts, enrollment of the fourth repeat cohort will proceed with the highest well-tolerated loading dose. Additional data on safety and tolerability will be presented during the poster session at AES.

Poster Session 2, Sunday, December 6, 4:00 pm - 5:00 pm, Hall D, Level 2 (Abstract 2.222)

Nathan B. Fountain 1, Gregory Krauss 2, Jouko Isojarvi 3, Deanne Dilley 3, Pamela Doty 3

1 University of Virginia, Charlottesville, Virginia; 2 John Hopkins University, Baltimore, Maryland; 3 Schwarz Biosciences (a member of the UCB Group), Raleigh, North Carolina

Important safety information about Vimpat® in the U.S.

Vimpat® (lacosamide) is a medicine that is use
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... College and university students around the ... new Introduction to Sociology offering, which ... based on each student’s behavior, knowledge, and aptitude. ... adaptive online curriculum resources that individualize each student’s ... general education offerings, enabling institutions to create efficiencies ...
(Date:5/22/2013)... 2013 TheBeautyPlace.com features Toppik and Bosley hair ... any remnants of thinning or balding hair. Hair loss treatments ... appearance of hair loss during this waiting period, one can ... as an alternative to hair transplant surgery in general. ... and an extremely effective way to eliminate the appearance of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Officials with ... that its cicada services are now in full effect ... that the cicada cycle emerges. , “The cicada ... year that they will emerge, so we’re now offering ... are well protected during the invasion,” said R. Brett ...
(Date:5/22/2013)... 22, 2013 2013 NBA Draft tickets ... Wednesday, May 22, 2013. , The 2013 NBA Draft will be ... the home of the Brooklyn Nets. The Barclays Center has ... Spectacular music artists such as Paul McCartney and Beyonce have already ... Cirque du Soleil will also perform at this state-of-the-art venue. ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2Health News:2013 NBA Draft Tickets: Cheap Concert Tickets Announces that Official Onsales for the 2013 NBA Draft Begin at 10:00 am Local Time on Wednesday, May 22, 2013 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3
... a leading global clinical,research organization, is pleased to ... at the JCAHPO annual continuing education,program. Diana who ... Cannula, worked in ophthalmic practice for several years,prior ... (CRA). The,meeting will take place in New Orleans, ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... MINNEAPOLIS /ST. PAUL (October 31, 2007) According to new ... information in most cases to apply a policy and ... the information. Medicare appears reluctant to aggressively enforce ... are inconsistent with scientific evidence. , By law, Medicare ...
... Video Component Enables Users to Upload Video Confessions/ ... on newfaceofresearch.com for Peer-to-Peer Viewing, PHILADELPHIA and ... Thomson Corporation (NYSE: TOC ; TSX: TOC) ... research and,business communities, today announced the launch of ...
... providing all current services, invest $20 million in ... ... Calif., Oct. 31 Prime Healthcare Services,Inc. (PHS), the owner ... today that Prime Healthcare Centinela, one,of its subsidiaries, has acquired ...
... Health,Services (MHS), a not-for-profit health care system with ... that it has selected,Integrated Healthcare Holdings, Inc. (IHHI) ... a partially physician-owned publicly traded hospital management,company, owns ... a total of,770 beds, 2787 employees and 1725 ...
Cached Medicine News:Health News:Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting 2Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 2Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 3Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 4Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2
(Date:5/22/2013)... , May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... present an overview of the company at the following conferences. ... , Presentation date: Wednesday May 29, 2013 , ... 2013 Global Healthcare Conference , Presentation date: Wednesday June ... A live webcast and 30-day ...
(Date:5/22/2013)... Mass. , May 22, 2013  Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... Elusys Therapeutics, Inc.,(Elusys), a privately held biopharmaceutical ... life-threatening infectious,diseases, today announced it has been ... development of Anthim(TM), the company,s late-stage anthrax,therapeutic. ... or in part with Federal,funds from the ...
... Trial Aims to Treat Renal Artery Obstructions and Lower ... Pressure in Patients Not Responding to Medication, ... today announced enrollment of the first patient in HERCULES ... and,Safety), a U.S. clinical trial designed to evaluate the ...
Cached Medicine Technology:Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 3
Castroviejo microscopic needle holder...
Dilator...
Microscopic scissors, curved...
Microscopic needle holder, curved...
Medicine Products: